These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 30851646

  • 1. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
    Raab M, Sanhaji M, Zhou S, Rödel F, El-Balat A, Becker S, Strebhardt K.
    Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
    [Abstract] [Full Text] [Related]

  • 2. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Raab M, Kobayashi NF, Becker S, Kurunci-Csacsko E, Krämer A, Strebhardt K, Sanhaji M.
    Int J Cancer; 2020 Feb 15; 146(4):1086-1098. PubMed ID: 31286496
    [Abstract] [Full Text] [Related]

  • 3. Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.
    Belur Nagaraj A, Kovalenko O, Avelar R, Joseph P, Brown A, Surti A, Mantilla S, DiFeo A.
    Clin Cancer Res; 2018 Sep 15; 24(18):4588-4601. PubMed ID: 29653924
    [Abstract] [Full Text] [Related]

  • 4. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
    Jemaà M, Kifagi C, Serrano SS, Massoumi R.
    Cell Physiol Biochem; 2020 Apr 08; 54(2):303-320. PubMed ID: 32259417
    [Abstract] [Full Text] [Related]

  • 5. Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy.
    Giovinazzi S, Bellapu D, Morozov VM, Ishov AM.
    Cell Cycle; 2013 Aug 15; 12(16):2598-607. PubMed ID: 23907120
    [Abstract] [Full Text] [Related]

  • 6. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R, Shi H, Ren F, Liu H, Zhang M, Deng Y, Li X.
    Oncol Rep; 2015 Mar 15; 33(3):1235-42. PubMed ID: 25592872
    [Abstract] [Full Text] [Related]

  • 7. Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – a critical role of Cdk1 in mitotic entry.
    Chang WL, Yu CC, Chen CS, Guh JH.
    Biochem Pharmacol; 2015 Mar 01; 94(1):12-21. PubMed ID: 25615907
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic relevance of the protein phosphatase 2A in cancer.
    Cunningham CE, Li S, Vizeacoumar FS, Bhanumathy KK, Lee JS, Parameswaran S, Furber L, Abuhussein O, Paul JM, McDonald M, Templeton SD, Shukla H, El Zawily AM, Boyd F, Alli N, Mousseau DD, Geyer R, Bonham K, Anderson DH, Yan J, Yu-Lee LY, Weaver BA, Uppalapati M, Ruppin E, Sablina A, Freywald A, Vizeacoumar FJ.
    Oncotarget; 2016 Sep 20; 7(38):61544-61561. PubMed ID: 27557495
    [Abstract] [Full Text] [Related]

  • 9. Nocodazole-Induced Expression and Phosphorylation of Anillin and Other Mitotic Proteins Are Decreased in DNA-Dependent Protein Kinase Catalytic Subunit-Deficient Cells and Rescued by Inhibition of the Anaphase-Promoting Complex/Cyclosome with proTAME but Not Apcin.
    Douglas P, Ye R, Radhamani S, Cobban A, Jenkins NP, Bartlett E, Roveredo J, Kettenbach AN, Lees-Miller SP.
    Mol Cell Biol; 2020 Jun 15; 40(13):. PubMed ID: 32284347
    [Abstract] [Full Text] [Related]

  • 10. Mitotic slippage: an old tale with a new twist.
    Sinha D, Duijf PHG, Khanna KK.
    Cell Cycle; 2019 Jan 15; 18(1):7-15. PubMed ID: 30601084
    [Abstract] [Full Text] [Related]

  • 11. Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics.
    Noack S, Raab M, Matthess Y, Sanhaji M, Krämer A, Győrffy B, Kaderali L, El-Balat A, Becker S, Strebhardt K.
    Oncotarget; 2018 May 25; 9(40):25842-25859. PubMed ID: 29899826
    [Abstract] [Full Text] [Related]

  • 12. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK, Wong OG, Wong ES, Chan KK, Ip PP, Tse KY, Cheung AN.
    Int J Cancer; 2018 Sep 15; 143(6):1456-1469. PubMed ID: 29663364
    [Abstract] [Full Text] [Related]

  • 13. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
    Pai HC, Kumar S, Shen CC, Liou JP, Pan SL, Teng CM.
    PLoS One; 2015 Sep 15; 10(4):e0123819. PubMed ID: 25874627
    [Abstract] [Full Text] [Related]

  • 14. Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis.
    Eckerdt F, Strebhardt K.
    Cancer Res; 2006 Jul 15; 66(14):6895-8. PubMed ID: 16849530
    [Abstract] [Full Text] [Related]

  • 15. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
    Gasca J, Flores ML, Giráldez S, Ruiz-Borrego M, Tortolero M, Romero F, Japón MA, Sáez C.
    Oncotarget; 2016 Aug 16; 7(33):52751-52765. PubMed ID: 27409838
    [Abstract] [Full Text] [Related]

  • 16. An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
    Wang X, Wu E, Wu J, Wang TL, Hsieh HP, Liu X.
    PLoS One; 2013 Aug 16; 8(6):e65686. PubMed ID: 23762410
    [Abstract] [Full Text] [Related]

  • 17. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K.
    Cancer Res; 2006 Jun 01; 66(11):5836-46. PubMed ID: 16740723
    [Abstract] [Full Text] [Related]

  • 18. c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability.
    Menssen A, Epanchintsev A, Lodygin D, Rezaei N, Jung P, Verdoodt B, Diebold J, Hermeking H.
    Cell Cycle; 2007 Feb 01; 6(3):339-52. PubMed ID: 17297307
    [Abstract] [Full Text] [Related]

  • 19. Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer.
    Chong T, Sarac A, Yao CQ, Liao L, Lyttle N, Boutros PC, Bartlett JMS, Spears M.
    J Ovarian Res; 2018 Apr 04; 11(1):27. PubMed ID: 29618387
    [Abstract] [Full Text] [Related]

  • 20. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
    Spänkuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K.
    Oncogene; 2007 Aug 23; 26(39):5793-807. PubMed ID: 17369857
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.